MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...
MARKHAM, Ontario--(BUSINESS WIRE)--Exact Imaging today announced results from its OPTIMUM clinical trial demonstrating the non-inferiority of its ExactVu™ micro-ultrasound platform to MRI ...
In a cohort of US veterans with prostate cancer who were on active surveillance, negative multiparametric MRI had a 75% negative predictive value for ruling out disease of grade group 2 or higher at ...
A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...
Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...
Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown. We invited 37,887 men who were 50 to 60 years of ...
A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade ...
Using MRI instead of CT guidance to zero in on prostate tumors enables more precise delivery of SBRT and lowers side effect rates. MRI vs CT guidance reduces side effects from prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback